title: Endothelin type A and B receptors in the control of afferent and efferent arterioles in mice.
abstract: BACKGROUND
  Endothelin 1 contributes to renal blood flow control and pathogenesis of kidney diseases. The differential effects, however, of endothelin 1 (ET-1) on afferent (AA) and efferent arterioles (EA) remain to be established.
  
  
  METHODS
  We investigated endothelin type A and B receptor (ETA-R, ETB-R) functions in the control of AA and EA. Arterioles of ETB-R deficient, rescued mice [ETB(-/-)] and wild types [ETB(+/+)] were microperfused.
  
  
  RESULTS
  ET-1 constricted AA stronger than EA in ETB(-/-) and ETB(+/+) mice. Results in AA: ET-1 induced similar constrictions in ETB(-/-) and ETB(+/+) mice. BQ-123 (ETA-R antagonist) inhibited this response in both groups. ALA-ET-1 and IRL1620 (ETB-R agonists) had no effect on arteriolar diameter. L-NAME did neither affect basal diameters nor ET-1 responses. Results in EA: ET-1 constricted EA stronger in ETB(+/+) compared to ETB(-/-). BQ-123 inhibited the constriction completely only in ETB(-/-). ALA-ET-1 and IRL1620 constricted only arterioles of ETB(+/+) mice. L-NAME decreased basal diameter in ETB(+/+), but not in ETB(-/-) mice and increased the ET-1 response similarly in both groups. The L-NAME actions indicate a contribution of ETB-R in basal nitric oxide (NO) release in EA and suggest dilatory action of ETA-R in EA.
  
  
  CONCLUSIONS
  ETA-R mediates vasoconstriction in AA and contributes to vasoconstriction in EA in this mouse model. ETB-R has no effect in AA but mediates basal NO release and constriction in EA. The stronger effect of ET-1 on AA supports observations of decreased glomerular filtration rate to ET-1 and indicates a potential contribution of ET-1 to the pathogenesis of kidney diseases.
authors.affiliation: Institute of Vegetative Physiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Janice
authors.initials: J
authors.lastname: Schildroth
authors.forename: Juliane
authors.initials: J
authors.lastname: Rettig-Zimmermann
authors.forename: Philipp
authors.initials: P
authors.lastname: Kalk
authors.forename: Andreas
authors.initials: A
authors.lastname: Steege
authors.forename: Michael
authors.initials: M
authors.lastname: Fähling
authors.forename: Mauricio
authors.initials: M
authors.lastname: Sendeski
authors.forename: Alexander
authors.initials: A
authors.lastname: Paliege
authors.forename: En Yin
authors.initials: EY
authors.lastname: Lai
authors.forename: Sebastian
authors.initials: S
authors.lastname: Bachmann
authors.forename: Pontus B
authors.initials: PB
authors.lastname: Persson
authors.forename: Berthold
authors.initials: B
authors.lastname: Hocher
authors.forename: Andreas
authors.initials: A
authors.lastname: Patzak
mesh_terms: D000818:Animals; D001160:Arterioles / Q000502:physiology*; D002478:Cells, Cultured; D016232:Endothelins / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D007678:Kidney Glomerulus / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics; D044022:Receptor, Endothelin A / Q000502:physiology*; D044023:Receptor, Endothelin B / Q000502:physiology*; D012079:Renal Circulation; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D016232:Endothelins; D012333:RNA, Messenger; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B